152 related articles for article (PubMed ID: 14988696)
1. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy.
Huber MA; Kunzi-Rapp K; Staib G; Scharffetter-Kochanek K
J Am Acad Dermatol; 2004 Mar; 50(3):475-6. PubMed ID: 14988696
[No Abstract] [Full Text] [Related]
2. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides.
Michaelis S; Cozzio A; Kempf W; Graf P; Burg G; Dummer R
Dermatology; 2004; 209(1):72-4. PubMed ID: 15237276
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
4. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J; Cowper S; Moss J; Girardi M
J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
[TBL] [Abstract][Full Text] [Related]
5. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
6. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
7. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
8. [Mycosis fungoid treated with oral bexarotene: study of 13 cases].
Roche Gamón E; Pérez Ferriols A; Vilata Corell JJ; Alegre de Miquel V
Med Clin (Barc); 2007 Nov; 129(17):677. PubMed ID: 18005638
[No Abstract] [Full Text] [Related]
9. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
10. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
11. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
[No Abstract] [Full Text] [Related]
12. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
13. Combining rexinoids with psoralen-ultraviolet A sheds light on the management of mycosis fungoides.
Ahmed Z; Piguet V
Br J Dermatol; 2012 Sep; 167(3):467. PubMed ID: 22924948
[No Abstract] [Full Text] [Related]
14. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
15. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
16. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides.
Pavlotsky F; Hodak E; Ben Amitay D; Barzilai A
J Am Acad Dermatol; 2014 Sep; 71(3):536-41. PubMed ID: 24836546
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
Coors EA; Von den Driesch P
Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
[No Abstract] [Full Text] [Related]
20. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides.
Lokitz ML; Wong HK
Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):255-7. PubMed ID: 17986063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]